The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index; 8 of the 23 sources its claims cite were checked for support.
Mechanisms of postprandial glucose counterregulation in man. Physiologic roles of glucagon and epinephrine vis-a-vis insulin in the prevention of hypoglycemia late after glucose ingestion
Open accessAbstract
The transition from exogenous glucose delivery to endogenous glucose production late after glucose ingestion is not solely attributable to dissipation of insulin and, therefore, must also involve factors that actively raise the plasma glucose concentration--glucose counterregulatory factors. We have shown that the secretion of two of these, glucagon and epinephrine, is specific for glucose ingestion and temporally related to the glucose counterregulatory process. To determine the physiologic roles of glucagon and epinephrine in postprandial glucose counterregulation, we produced pharmacologic interventions that resulted in endogenous glucagon deficiency with and without exogenous glucagon replacement, adrenergic blockade, and adrenergic blockade coupled with glucagon deficiency starting 225 min after the ingestion of 75 g of glucose in normal subjects. Also, we assessed the effect of endogenous epinephrine deficiency alone and in combination with glucagon deficiency late after glucose ingestion in bilaterally adrenalectomized subjects. Glucagon deficiency resulted in nadir plasma glucose concentrations that were approximately 30% lower (P less than 0.01) than control values, but did not cause hypoglycemia late after glucose ingestion. This effect was prevented by glucagon replacement. Neither adrenergic blockade nor epinephrine deficiency alone impaired the glucose counterregulatory process. However, combined glucagon and epinephrine deficiencies resulted in a progressive fall in mean plasma glucose to a hypoglycemic level late after glucose ingestion; the final glucose concentration was 40% lower (P less than 0.02) than the control (epinephrine deficient) value in these patients, and was nearly 50% lower (P less than 0.001) than the control value and approximately 30% lower (P less than 0.05) than the glucagon-deficient value in normal subjects. We conclude (a) the transition from exogenous glucose delivery to endogenous glucose production late after glucose ingestion is the result of the coordinated diminution of insulin secretion and the resumption of glucagon secretion. (b) Epinephrine does not normally play a critical role in this process, but enhanced epinephrine secretion compensates largely and prevents hypoglycemia when glucagon secretion is deficient.
Overview
CoChat Summary
TL;DR
In normal and bilaterally adrenalectomized humans, glucagon deficiency late after oral glucose lowered plasma glucose but did not cause hypoglycemia unless epinephrine was also deficient. The transition from exogenous glucose delivery to endogenous glucose production after glucose ingestion depends on coordinated insulin diminution and glucagon resumption, with epinephrine compensating when glucagon is deficient.
Key findings
Glucagon deficiency (somatostatin plus insulin replacement) lowered nadir plasma glucose to 62±3 mg/dl at 275 min versus 85±6 mg/dl during saline (P < 0.01), about 30% lower, and this was prevented by glucagon replacement. Neither combined α/β-adrenergic blockade nor epinephrine deficiency alone impaired late postprandial glucose counterregulation. Combined glucagon and epinephrine deficiency caused progressive hypoglycemia: in adrenalectomized patients, final glucose was 47±9 mg/dl at 305 min versus 78±10 mg/dl with saline (P < 0.02), 88±4 mg/dl in normal saline controls (P < 0.001), and 68±3 mg/dl in glucagon-deficient normal subjects (P < 0.05). The authors conclude epinephrine is not normally critical but compensates largely and prevents hypoglycemia when glucagon secretion is deficient.
Methods
Eight normal adults (7 male, 1 female; ages 23–28 yr) and five bilaterally adrenalectomized patients (2 male, 3 female; ages 24–57 yr) with deficient epinephrine response to insulin-induced hypoglycemia ingested 75 g glucose after an overnight fast. Interventions began 225–305 min after glucose: saline; somatostatin (250 μg/h) with insulin replacement (100 μU/kg/min); somatostatin plus insulin plus glucagon replacement (1.0 or 1.5 ng/kg/min); phentolamine plus propranolol; and phentolamine-propranolol plus somatostatin with insulin replacement in normal subjects; adrenalectomized patients received saline or somatostatin with insulin replacement. Plasma glucose, insulin, glucagon, epinephrine, norepinephrine, cortisol, and growth hormone were measured, with paired or unpaired t tests and P < 0.05 considered significant.
Limitations
Stated: phentolamine and propranolol are competitive antagonists that markedly elevate plasma catecholamines, so negative findings must be interpreted cautiously and positive findings may underestimate normal adrenergic effects; somatostatin produced only small decreases in measured immunoreactive glucagon, and peripheral venous glucagon may not reflect biologically active portal glucagon. Stated: the adrenalectomized patients were not matched to normal subjects, had baseline and post-glucose hyperinsulinemia probably due to obesity, and one patient’s study was discontinued for neuroglycopenia with the 35 mg/dl value carried forward, likely making the final mean lower had the study continued. Stated: the study addresses rapid glucose counterregulation, and mechanisms of more gradual counterregulation may differ; other hormones, neural mechanisms, or autoregulation are not excluded.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
7 Valid · 1 Not valid · 6 Not checked · 41 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“plasma epinephrine concentrations do not commonly achieve the threshold level required to affect basal glucose metabolism (7).”
What the sources say
- Disputedcites [7] 7. Clutter, W. E., D. M. Bier, S. D. Shah, and P. E. Cryer. 1980. Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. J. Clin. Invest. 66:94-101. sourceExperimental — accuracy not yet measured
The Discussion (p. 6) places the threshold for changes in glucose production and clearance at 150–200 pg/ml and explicitly says that thresholds for direct metabolic actions lie within the commonly achieved physiologic range. That contradicts the claim that plasma epinephrine concentrations do not commonly reach the threshold needed to affect glucose metabolism. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“cortisol secretion is unaltered (1).”
What the sources say
- Supportedcites [1] 1. Tse, T. F., W. E. Clutter, S. D. Shah, J. P. Miller, and P. E. Cryer. 1983. Neuroendocrine responses to glucose ingestion in man: specificity, temporal relationships, and quantitative aspects. J. Clin. Invest. 72:270-277. source
The Discussion states that cortisol levels were unaffected after glucose ingestion. The results also report that plasma cortisol curves were similar after ingestion of the four test solutions, supporting the claim in the context of this study. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Also, glucagon and epinephrine are rapidly acting counterregulatory hormones (4, 5).”
What the sources say
- Not checked — no full text of the sourcecites [4] 4. Rizza, R. A., M. W. Haymond, P. E. Cryer, and J. E. Gerich. 1979. Differential effects of physiologic concentrations of epinephrine on glucose production and disposal in man. Am. J. Physiol. 237:E356-E362. source
- Partly supportedcites [5] 5. Rizza, R., C. Verdonk, J. Miles, F. J. Service, and J. E. Gerich. 1979. Effect of intermittent endogenous hyperglucagonemia on glucose homeostasis in normal and diabetic man. J. Clin. Invest. 63:1119-1123. sourceExperimental — accuracy not yet measured
The Results (page unavailable) report that plasma glucose and glucose appearance promptly increased when glucagon infusion was increased, supporting a rapid glucagon effect. The paper does not establish the corresponding claim about epinephrine; a search for epinephrine found no passage addressing its action. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our study of the specificity, temporal relationships, and quantitative aspects of the neuroendocrine responses to glucose ingestion (1) indicates that this transition is not solely the result of the dissipation of insulin and, therefore, must also involve a factor or factors that actively raise the plasma glucose concentration— glucose counterregulatory factors.”
What the sources say
- Supportedcites [1] 1. Tse, T. F., W. E. Clutter, S. D. Shah, J. P. Miller, and P. E. Cryer. 1983. Neuroendocrine responses to glucose ingestion in man: specificity, temporal relationships, and quantitative aspects. J. Clin. Invest. 72:270-277. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“3,500-D glucagon is preferentially extracted by the liver (18, 19).”
What the sources say
- Supportedcites [18] 18. Jaspan, J. B., A. H.-J. Huen, C. G. Morley, A. R. Moossa, and A. H. Rubenstein. 1977. The role of the liver in glucagon metabolism. J. Clin. Invest. 60:421-428. source
The Discussion states that the liver extracts the 3,500-dalton fraction while the other molecular species are not removed to any extent. The Abstract reports selective hepatic extraction of that fraction in the animals studied. (LLM, conf=0.95)
- Not matchedcites [19]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
34 more claims
Create a free account to see all 55 claims and every source verdict.
- It may state two separate claims as one. 11
- Probably not a substantial claim. 6
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and postabsorptive plasma glucose concentrations are not discernibly reduced in epinephrine-deficient (adrenalectomized) persons (3, 9).”
From Epinephrine supports the postabsorptive plasma glucose concentration and prevents hypoglycemia when glucagon secretion is deficient in man (1984) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second, in both hypoglycemic glucose counterregulation (1-7) and in another model of nonhypoglycemic glucose counterregulation (9), adrenomedullary epinephrine, but not sympathetic neural norepinephrine, compensates for deficient glucagon secretion.”
From Epinephrine supports the postabsorptive plasma glucose concentration and prevents hypoglycemia when glucagon secretion is deficient in man (1984) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Thus, the principles of hypoglycemic glucose counterregulation (1-7) and those of nonhypoglycemic glucose counterregulation in both the postprandial (8, 9) and the postabsorptive states are fundamentally the same.”
From Epinephrine supports the postabsorptive plasma glucose concentration and prevents hypoglycemia when glucagon secretion is deficient in man (1984) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“More recently it has been shown that the same principles apply to nonhypoglycemic glucose counterregulation”
From Epinephrine supports the postabsorptive plasma glucose concentration and prevents hypoglycemia when glucagon secretion is deficient in man (1984) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ DISCUSSION · p. 6
“somatostatin (with insulin replacement) was infused from 220 through 305 miņ in adrenalectomized subjects”
§ METHODS · p. 2
“Interventions, begun at 1040 h and continued through 1200 h (225 through 305 min after the start of glucose ingestion)”
Citations
Cites
Cryer, P. E., Haymond, M. W., Santiago, J. V., & Shah, S. D. (1976) · New England Journal of Medicine · doi:10.1056/nejm197609092951101 · Cited by 1,101
Self-citationClutter, W. E., Bier, D. M., Shah, S. D., & Cryer, P. E. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109840 · Cited by 576
Self-citationRole of Glucagon, Catecholamines, and Growth Hormone in Human Glucose Counterregulation
Rizza, R. A., Cryer, P. E., & Gerich, J. E. (1979) · Journal of Clinical Investigation · doi:10.1172/jci109464 · Cited by 421
Self-citationSHAMOON, H., HENDLER, R., & SHERWIN, R. S. (1981) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-52-6-1235 · Cited by 295
Glucose Counterregulation in Man
Cryer, P. E. (1981) · Diabetes · doi:10.2337/diab.30.3.261 · Cited by 270
Self-citationInitial splanchnic extraction of ingested glucose in normal man
Radziuk, J., McDonald, T. J., Rubenstein, D., & Dupre, J. (1978) · Metabolism · doi:10.1016/0026-0495(78)90003-3 · Cited by 207
Hormonal mechanisms of recovery from insulin-induced hypoglycemia in man.
Gerich, J., Davis, J., Lorenzi, M., Rizza, R., Bohannon, N., Karam, J., Lewis, S., Kaplan, R., Schultz, T., & Cryer, P. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.236.4.e380 · Cited by 183
Self-citationMACGORMAN, L. R., RIZZA, R. A., & GERICH, J. E. (1981) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-53-3-556 · Cited by 175
SANTIAGO, J. V., CLARKE, W. L., SHAH, S. D., & CRYER, P. E. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-51-4-877 · Cited by 166
Self-citationDifferential effects of epinephrine on glucose production and disposal in man.
Rizza, R., Haymond, M., Cryer, P., & Gerich, J. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.4.e356 · Cited by 115
Self-citation
Cited by
Service, F. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504273321707 · Cited by 503
Schwartz, N. S., Clutter, W. E., Shah, S. D., & Cryer, P. E. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112884 · Cited by 394
Self-citationFirth, R. G., Bell, P. M., Marsh, H. M., Hansen, I., & Rizza, R. A. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112467 · Cited by 280
Glucose counterregulation, hypoglycemia, and intensive insulin therapy in diabetes mellitus
Epstein, F. H., Cryer, P. E., & Gerich, J. E. (1985) · New England Journal of Medicine · doi:10.1056/nejm198507253130405 · Cited by 273
Self-citationPlow, E., McEver, R., Coller, B., Woods, V. J., Marguerie, G., & Ginsberg, M. (1985) · Blood · doi:10.1182/blood.v66.3.724.724 · Cited by 257
Metadata
- Authors
- Tse, T. F., Clutter, W. E., Shah, S. D., & Cryer, P. E.
- Affiliations
- Washington University in St. Louis (US)
- Venue
- Journal of Clinical Investigation
- Published
- 1983-07-01
- Volume
- 72
- Issue
- 1
- Pages
- 278-286
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1129183
- OpenAlex
- W2012300813
- Cited by
- 73
- References
- 25
- Citations by year
- 2021: 1 · 2017: 1 · 2016: 2 · 2014: 1 · 2013: 1
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucagon, epinephrine, insulin, hypoglycemia, glucagon deficiency, adrenergic blockade, adrenalectomy, endogenous glucose production, plasma glucose
- MeSH terms
- Adrenalectomy, Adult, Blood Glucose, Epinephrine, Female, Glucagon, Glucose, Humans, Insulin, Male, Phentolamine, Propranolol, Somatostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms of postprandial glucose counterregulation in man. Physiologic roles of glucagon and epinephrine vis-a-vis insulin in the prevention of hypoglycemia late after glucose ingestion. https://app.cochat.ai/papers/10.1172/jci110967
- The paper
- Tse, T. F., Clutter, W. E., Shah, S. D., & Cryer, P. E. (1983). Mechanisms of postprandial glucose counterregulation in man. Physiologic roles of glucagon and epinephrine vis-a-vis insulin in the prevention of hypoglycemia late after glucose ingestion. Journal of Clinical Investigation. https://doi.org/10.1172/jci110967
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.